Methods of Treating Inflammatory Pain

Abstract

The invention relates to an anti-CGRP antibody for use in the prevention and/or treatment of inflammatory pain and/or symptoms of inflammatory pain, and to a method of treating and/or preventing inflammatory pain and/or symptoms of inflammatory pain using an anti-CGRP antibody.

1 . A method for preventing and/or treating inflammatory pain and/or symptoms of inflammatory pain, comprising peripheral administration to the individual of an effective amount of an anti-CGRP antagonist antibody. 
     
     
         2 . The method according to  claim 1 , wherein the medicament is prepared to be peripherally administered. 
     
     
         3 . The method according to  claim 1 , wherein the medicament is administered peripherally. 
     
     
         4 . The method according to  claim 1 , wherein the medicament is prepared to be administered orally, sublingually, via inhalation, transdermally, subcutaneously, intravenously, intra-arterially, intra-articularly, peri-articularly, locally and/or intramuscularly. 
     
     
         5 . The method according to  claim 4 , wherein the medicament is prepared to be administered subcutaneously or intravenously. 
     
     
         6 . The method according to  claim 1 , wherein the anti-CGRP antagonist antibody acts peripherally on administration. 
     
     
         7 . The method according to  claim 1 , wherein the inflammatory pain is arthritic pain. 
     
     
         8 . The method according to  claim 7 , wherein the arthritic pain is osteoarthritis pain. 
     
     
         9 . The method according to  claim 1 , wherein the anti-CGRP antagonist antibody:
 (a) binds to CGRP;   (b) blocks CGRP from binding to its receptor;   (c) blocks or decreases CGRP receptor activation;   (d) inhibits blocks, suppresses or reduces CGRP biological activity;   (e) increases clearance of CGRP; and/or   (g) inhibits CGRP synthesis, production or release.   
     
     
         10 . The method according to  claim 1 , wherein the anti-CGRP antagonist antibody:
 (i) is a human antibody,   (ii) is a humanized antibody,   (iii) is a monoclonal antibody,   (iv) binds CGRP with a Kd of 50 nM or less (as measured by surface plasmon resonance at 37° C.); and/or   (v) has a half life in-vivo of at least 7 days.   
     
     
         11 . The method according to  claim 1 , wherein the anti-CGRP antagonist antibody specifically binds to the C-terminal region of CGRP. 
     
     
         12 . The method according to  claim 10 , wherein the anti-CGRP antagonist antibody specifically recognises the epitope defined by the sequence GSKAF. 
     
     
         13 . The method according to  claim 1 , wherein the anti-CGRP antibody comprises a VH domain that is at least 90% identical in amino acid sequence to SEQ ID NO: 1 or 19. 
     
     
         14 . The method according to  claim 1 , wherein the anti-CGRP antibody comprises a VL domain that is at least 90% identical in amino acid sequence to SEQ ID NO: 2 or 20. 
     
     
         15 . The method according to  claim 14 , wherein the anti-CGRP antibody further comprises a VH domain that is at least 90% identical in amino acid sequence to SEQ ID NO: 1 or 19. 
     
     
         16 . The method according to  claim 1 , wherein the anti-CGRP antibody comprises at least one CDR selected from the group consisting of:
 (a) CDR H1 as set forth in SEQ ID NO: 3 or 21;   (b) CDR H2 as set forth in SEQ ID NO: 4 or 22;   (c) CDR H3 as set forth in SEQ ID NO: 5 or 23;   (d) CDR L1 as set forth in SEQ ID NO: 6 or 24;   (e) CDR L2 as set forth in SEQ ID NO: 7 or 25;   (f) CDR L3 as set forth in SEQ ID NO: 8 or 26; and   (g) variants of L1, L2 and H2.   
     
     
         17 . The method according to  claim 1 , wherein the anti-CGRP antibody comprises a VH domain that is at least 90% identical in amino acid sequence to SEQ ID NO: 1 and a VL domain that is at least 90% identical in amino acid sequence to SEQ ID NO: 2. 
     
     
         18 . The method according to  claim 1 , wherein the anti-CGRP antibody comprises a heavy chain produced by the expression vector with ATCC Accession No. PTA-6867. 
     
     
         19 . The method according to  claim 1 , wherein the anti-CGRP antibody comprises a light chain produced by the expression vector with ATCC Accession No. PTA-6866. 
     
     
         20 . The method according to  claim 1 , wherein the anti-CGRP antibody is produced by the expression vectors with ATCC Accession Nos. PTA-6867 and PTA-6866. 
     
     
         21 .- 31 . (canceled)